General Information of Drug Transporter (DT)
DT ID DTD0031 Transporter Info
Gene Name SLCO2B1
Transporter Name Organic anion transporting polypeptide 2B1
Gene ID
11309
UniProt ID
O94956
Post-Translational Modification of This DT
Overview of SLCO2B1 Modification Sites with Functional and Structural Information
Sequence
PTM type
X-N-glycosylation X-Phosphorylation X: Amino Acid

N-glycosylation

  Asparagine

          2 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLCO2B1 [1]

Role of PTM

Potential impacts

Modified Residue

Asparagine

Modified Location

176

Experimental Method

Co-Immunoprecipitation

Detailed Description

N-linked Glycosylation at SLCO2B1 Asparagine 176 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLCO2B1 [1]

Role of PTM

Potential impacts

Modified Residue

Asparagine

Modified Location

538

Experimental Method

Co-Immunoprecipitation

Detailed Description

N-linked Glycosylation at SLCO2B1 Asparagine 538 has the potential to affect its expression or activity.

  Cysteine

        10 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Impairing the function of SLCO2B1 [2]

Role of PTM

Protein Activity Modulation

Modified Residue

Cysteine

Modified Location

489

Modified State

Cysteine to Alanine mutation

Experimental Material(s)

Chinese hamster ovary subclone (CHO-K1) cells

Experimental Method

Co-Immunoprecipitation

Detailed Description

Removal of the Glycosylation at SLCO2B1 Cysteine 489 (i.e. Cysteine to Alanine mutation) have been reported to impaire its transport function.

  PTM Phenomenon 2

Impairing the function of SLCO2B1 [2]

Role of PTM

Protein Activity Modulation

Modified Residue

Cysteine

Modified Location

495

Modified State

Cysteine to Alanine mutation

Experimental Material(s)

Chinese hamster ovary subclone (CHO-K1) cells

Experimental Method

Co-Immunoprecipitation

Detailed Description

Removal of the Glycosylation at SLCO2B1 Cysteine 495 (i.e. Cysteine to Alanine mutation) have been reported to impaire its transport function.

  PTM Phenomenon 3

Impairing the function of SLCO2B1 [2]

Role of PTM

Protein Activity Modulation

Modified Residue

Cysteine

Modified Location

504

Modified State

Cysteine to Alanine mutation

Experimental Material(s)

Chinese hamster ovary subclone (CHO-K1) cells

Experimental Method

Co-Immunoprecipitation

Detailed Description

Removal of the Glycosylation at SLCO2B1 Cysteine 504 (i.e. Cysteine to Alanine mutation) have been reported to impaire its transport function.

  PTM Phenomenon 4

Impairing the function of SLCO2B1 [2]

Role of PTM

Protein Activity Modulation

Modified Residue

Cysteine

Modified Location

516

Modified State

Cysteine to Alanine mutation

Experimental Material(s)

Chinese hamster ovary subclone (CHO-K1) cells

Experimental Method

Co-Immunoprecipitation

Detailed Description

Removal of the Glycosylation at SLCO2B1 Cysteine 516 (i.e. Cysteine to Alanine mutation) have been reported to impaire its transport function.

  PTM Phenomenon 5

Impairing the function of SLCO2B1 [2]

Role of PTM

Protein Activity Modulation

Modified Residue

Cysteine

Modified Location

520

Modified State

Cysteine to Alanine mutation

Experimental Material(s)

Chinese hamster ovary subclone (CHO-K1) cells

Experimental Method

Co-Immunoprecipitation

Detailed Description

Removal of the Glycosylation at SLCO2B1 Cysteine 520 (i.e. Cysteine to Alanine mutation) have been reported to impaire its transport function.

  PTM Phenomenon 6

Impairing the function of SLCO2B1 [2]

Role of PTM

Protein Activity Modulation

Modified Residue

Cysteine

Modified Location

539

Modified State

Cysteine to Alanine mutation

Experimental Material(s)

Chinese hamster ovary subclone (CHO-K1) cells

Experimental Method

Co-Immunoprecipitation

Detailed Description

Removal of the Glycosylation at SLCO2B1 Cysteine 539 (i.e. Cysteine to Alanine mutation) have been reported to impaire its transport function.

  PTM Phenomenon 7

Impairing the function of SLCO2B1 [2]

Role of PTM

Protein Activity Modulation

Modified Residue

Cysteine

Modified Location

541

Modified State

Cysteine to Alanine mutation

Experimental Material(s)

Chinese hamster ovary subclone (CHO-K1) cells

Experimental Method

Co-Immunoprecipitation

Detailed Description

Removal of the Glycosylation at SLCO2B1 Cysteine 541 (i.e. Cysteine to Alanine mutation) have been reported to impaire its transport function.

  PTM Phenomenon 8

Impairing the function of SLCO2B1 [2]

Role of PTM

Protein Activity Modulation

Modified Residue

Cysteine

Modified Location

553

Modified State

Cysteine to Alanine mutation

Experimental Material(s)

Chinese hamster ovary subclone (CHO-K1) cells

Experimental Method

Co-Immunoprecipitation

Detailed Description

Removal of the Glycosylation at SLCO2B1 Cysteine 553 (i.e. Cysteine to Alanine mutation) have been reported to impaire its transport function.

  PTM Phenomenon 9

Decreasing the membrane localization and transport function of the SLCO2B1 [2]

Role of PTM

Trafficking to Plasma Membrane

Affected Drug/Substrate

Estrone-3-sulfate and Dehydroepiandrosterone sulfate

Results for Drug

Decreasing the transport of estrone-3-sulfate and dehydroepiandrosterone sulfate

Modified Residue

Cysteine

Modified Location

493

Modified State

Cysteine to Alanine mutation

Experimental Material(s)

Chinese hamster ovary subclone (CHO-K1) cells

Experimental Method

Co-Immunoprecipitation

Detailed Description

Removal of the Glycosylation at SLCO2B1 Cysteine 493 (i.e. Cysteine to Alanine mutation) have been reported to decrease its membrane localization and transport function.

  PTM Phenomenon 10

Decreasing the membrane localization and transport function of the SLCO2B1 [2]

Role of PTM

Trafficking to Plasma Membrane

Affected Drug/Substrate

Estrone-3-sulfate and Dehydroepiandrosterone sulfate

Results for Drug

Decreasing the transport of estrone-3-sulfate and dehydroepiandrosterone sulfate

Modified Residue

Cysteine

Modified Location

557

Modified State

Cysteine to Alanine mutation

Experimental Material(s)

Chinese hamster ovary subclone (CHO-K1) cells

Experimental Method

Co-Immunoprecipitation

Detailed Description

Removal of the Glycosylation at SLCO2B1 Cysteine 557 (i.e. Cysteine to Alanine mutation) have been reported to decrease its membrane localization and transport function.

Phosphorylation

  Serine

          6 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLCO2B1 [3] , [4]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

34

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLCO2B1 Serine 34 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLCO2B1 [5]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

264

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLCO2B1 Serine 264 has the potential to affect its expression or activity.

  PTM Phenomenon 3

Have the potential to influence SLCO2B1 [6] , [7]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

320

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLCO2B1 Serine 320 has the potential to affect its expression or activity.

  PTM Phenomenon 4

Have the potential to influence SLCO2B1 [8] , [9]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

333

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLCO2B1 Serine 333 has the potential to affect its expression or activity.

  PTM Phenomenon 5

Have the potential to influence SLCO2B1 [10] , [11]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

687

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLCO2B1 Serine 687 has the potential to affect its expression or activity.

  PTM Phenomenon 6

Have the potential to influence SLCO2B1 [10] , [11]

Role of PTM

Potential impacts

Modified Residue

Serine

Modified Location

688

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLCO2B1 Serine 688 has the potential to affect its expression or activity.

  Threonine

          2 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLCO2B1 [12]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

133

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLCO2B1 Threonine 133 has the potential to affect its expression or activity.

  PTM Phenomenon 2

Have the potential to influence SLCO2B1 [6] , [13]

Role of PTM

Potential impacts

Modified Residue

Threonine

Modified Location

318

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLCO2B1 Threonine 318 has the potential to affect its expression or activity.

  Tyrosine

          1 PTM Phenomena Related to This Residue Click to Show/Hide the Full List

  PTM Phenomenon 1

Have the potential to influence SLCO2B1 [14]

Role of PTM

Potential impacts

Modified Residue

Tyrosine

Modified Location

144

Experimental Method

Co-Immunoprecipitation

Detailed Description

Phosphorylation at SLCO2B1 Tyrosine 144 has the potential to affect its expression or activity.
References
1 dbPTM in 2022: an updated database for exploring regulatory networks and functional associations of protein post-translational modifications. Nucleic Acids Res. 2022 Jan 7;50(D1):D471-D479. (ID: SO2B1_HUMAN)
2 Functional analysis of the extracellular cysteine residues in the human organic anion transporting polypeptide, OATP2B1. Mol Pharmacol. 2006 Sep;70(3):806-17.
3 Super-SILAC mix coupled with SIM/AIMS assays for targeted verification of phosphopeptides discovered in a large-scale phosphoproteome analysis of hepatocellular carcinoma. J Proteomics. 2017 Mar 22;157:40-51.
4 Integrated analysis of global proteome, phosphoproteome, and glycoproteome enables complementary interpretation of disease-related protein networks. Sci Rep. 2015 Dec 11;5:18189.
5 Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics. 2014 Jul;13(7):1690-704.
6 UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 2019 Jan 8;47(D1):D506-D515.
7 Integrating proteomics with electrochemistry for identifying kinase biomarkers. Chem Sci. 2015 Aug 1;6(8):4756-4766.
8 iTRAQ labeling is superior to mTRAQ for quantitative global proteomics and phosphoproteomics. Mol Cell Proteomics. 2012 Jun;11(6):M111.014423.
9 Systematic analysis of protein phosphorylation networks from phosphoproteomic data. Mol Cell Proteomics. 2012 Oct;11(10):1070-83.
10 Identification of Missing Proteins in the Phosphoproteome of Kidney Cancer. J Proteome Res. 2017 Dec 1;16(12):4364-4373.
11 Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016 Jun 2;534(7605):55-62.
12 FAIMS and Phosphoproteomics of Fibroblast Growth Factor Signaling: Enhanced Identification of Multiply Phosphorylated Peptides. J Proteome Res. 2015 Dec 4;14(12):5077-87.
13 A Methodological Assessment and Characterization of Genetically-Driven Variation in Three Human Phosphoproteomes. Sci Rep. 2018 Aug 14;8(1):12106.
14 Citric acid-assisted two-step enrichment with TiO2 enhances the separation of multi- and monophosphorylated peptides and increases phosphoprotein profiling. J Proteome Res. 2013 Jun 7;12(6):2467-76.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.